Fritextsökning
Innehållstyper
-
Virology professor on the threat from X: ”The next pandemic could be worse“
The question is not if, but when we will be affected by a new unknown virus that causes yet another pandemic. Are we sufficiently prepared? "Absolutely not!", r...
-
Southern Swedish company Aqilion develops drug for eosinophilic esophagitis
When Aqilion began developing a drug for eosinophilic esophagitis, the molecule was classified as an orphan drug. But the prevalence of the disease now appears ...
-
The top five most expensive drugs in 2025
New advanced therapeutic medicines are reaching the market, but their price tags remain exceptionally high. This year’s ranking of the most expensive drugs in t...
-
Investigations against AstraZeneca: ”Chinese interests may be behind them”
Why are there several investigations against AstraZeneca employees in China right now? Life Science Sweden continues to seek answers.
-
Karolinska Development tar in kapital – och byter namn
Life science-investmentbolaget Karolinska Development föreslår en företrädesemission om cirka 203 miljoner kronor före transaktionskostnader.
-
Svenskt biotechbolag tar in 153 miljoner till cancerstudie
One-carbon Therapeutics, ett svenskt biotechbolag med inriktning på svårbehandlad cancer, har tagit in 153 miljoner kronor i en övertecknad investeringsrunda.
-
Lundbeck kliver in i budstrid om narkolepsibolag
En budstrid har brutit ut om det irländska biotechbolaget Avadel Pharmaceuticals och dess potentiella storsäljare inom narkolepsi och hypersomni.
-
Charged with illegal pharmaceutical sales – alleged earnings of 23 million
For at least five years, two men allegedly carried out illegal sales of pharmaceuticals and supplements, amassing millions. They are now facing charges at Söder...
-
Spago Nanomedical tar in 25 miljoner – emission övertecknad
Lundabaserade Spago Nanomedical har slutfört sin företrädesemission som tecknades till 105,7 procent. Bolaget tillförs därmed cirka 25 miljoner kronor före kostnader.
-
Swedish team tests Alzheimer antibody for brain imaging
Recent breakthroughs in Alzheimer’s treatment have increased the need for precise diagnostics in the field. Researchers in Uppsala are working to develop improv...
-
New moves around Nykode's management – withdrawal of resignations
Norwegian Nykode Therapeutics is reinstating members of the management team who previously announced their resignations.
-
Xbrane skickar in ny ansökan efter FDA-bakslag
Solnaföretaget Xbrane har satt en tidplan för att åter skicka in en ansökan för sin biosimliar för Lucentis.
-
Several departures at the top at Nykode
Members of both the management and the board are leaving the Norwegian biotech company Nykode.
-
Robotkirurgi ska prövas som behandling mot Alzheimers sjukdom
Det amerikansk-italienska medtechbolaget Medical Microinstruments (MMI) har fått godkännande från FDA att inleda en klinisk studie där robotassisterad mikrokiru...
-
Roche joins Medicon Village
Roche and Medicon Village Innovation have signed an agreement for deeper collaboration. “The fact that Roche is now becoming part of this environment further st...
-
Ukraine war fuels rise of totally resistent bacteria
War-torn Ukraine is not just suffering from hostile attacks from a foreign aggressor, but also from the threat of a totally resistant and contagious bacteria.
-
New findings on the diseases that crushed Napoleon’s army
As if cold, starvation, and typhus weren’t enough. New research reveals that Napoleon’s defeated army also suffered from paratyphoid fever and relapsing fever d...
-
Partial court victory for entrepreneur who lost his company
Swedish life science entrepreneur Mikael Kubista has won the first round against a law firm that he, along with other co-owners, sued for negligent advice in co...
-
Lovande data för borreliavaccin – ansökan kan lämnas in 2026
Franska vaccinspecialisten Valneva har rapporterat positiva fas II-data för vaccinkandidaten VLA15 mot borrelia som utvecklas tillsammans med Pfizer.
-
CTC Clinical Trial Consultants AB
-
Mikael Kubista back with new venture after turbulent exit
Entrepreneur and researcher Mikael Kubista is starting a new company. Now he is also free to comment on the sequence of events that led to him losing ownership ...
-
Shaping the Future of Metrology – Live in Your Region
Insights into our event series.
-
Cost-efficient development of laboratory devices
8 ways to optimise development costs and speed up processes
-
Enkelt test kan förutsäga leversjukdom - ”Bygger på tre enkla blodprover”
Ett blodtest, utvecklat av forskare vid Karolinska institutet, kan förutsäga risken att utveckla allvarlig leversjukdom, enligt en ny studie